Indus Biotherapeutics


Home		Feedback		Sitemap		Contact

We believe in providing the best in terms of quality
products and professional services...

Home » Products & Services » EOP - Product Information

ERYKINE® & EPOFIT® RECOMBINANT HUMAN ERYTHROPOIETIN(rHu EPO)

Find Products & Services:

Neukine@ - Recombinant Human Granulocyte Colony stimulating Factor (rHu G - CSF)

Description

Erythropoietin is a glycoprotein which stimulates red blood cell production. In health individuals, it is produced in the kidney and stimulates the di and differentiation of committed erythroid progenitors in the bone marrow.

Recombinant Human Erythropoietin (rHu EPO), also called as Epoetin alpha, is a 165 amino acid protein with a molecular mass of 30.6kDa. The rHu EPO of Intas Pharmaceuticals is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product contains the identical amino acid sequence of natural Erythropoietin.

rHu EPO is used clinically for prevention and treatment of chemotherapy-induced neutropenia and Renal failure.

Manufacturing process:

Intas Erythropoietin is produced in genetically engineered CHO cells. The product is expressed and secreted into the medium. After cell culture, the medium is harvested and the product is purified by a series of chromatographic steps to produce highly purified Erythropoietin..

The finished product (Erykine® & Epofit®) is manufactured by formulating the Erythropoietin drug substance into Citrate buffer with other excipients.

Available Dosage Forms

Erykine® is available in pre-filled, preservative free, single dose syringe containing 10,000 Units/mL (Erykine 10K) and 40,000 Units/mL (Erykine 40K) and is targeted for Treatment of Anemia in Cancer Patients on Chemotherapy.

Epofit ® is available in pre-filled, preservative free, single dose syringe containing 2,000 Units/mL (Epofit 2K) and 4,000 Units/mL (Epofit 4K) and is targeted for Chronic Renal Failure Patients.

Current regulatory status

Presently, Erykine® & Epofit® are marketed in India. Registration dossiers for marketing approval are available as per CTD format.

Product quality

The product undergoes comprehensive physicochemical characterization and testing as per European Pharmacopoeia (EP) by methods such as isoelectric focusing, Western blotting, gel electrophoresis, mass spectrometry, N-terminal sequencing, peptide mapping, in-vivo bioassay and the product is found to be identical to the reference standard.

The activity and purity in terms of unrelated impurities (host protein and nucleic acids from CHO cells) as well as related impurities such as aggregates and other variants is comparable to that of the reference standard. The CHO cell-derived impurities are at ppm levels are in conformance with WHO and EMEA norms.

For further product information, please contact our medical information department at 02717-550100 or Business development.

info@indusbio.co.in